DDInter1217 DDInter915
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Miglitol {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Miglitol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Miglitol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Miglitol may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)